Back to Search
Start Over
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia
- Source :
- GlobeNewswire. September 4, 2019
- Publication Year :
- 2019
-
Abstract
- LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sep 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.598377589